Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +447.83% and +974.37%, respectively, for the quarter ...
Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027- ...
Collaboration revenue increased to $83.5 million from $8.2 million a year earlier. The $75.4 million increase primarily reflected a $74.1 million cumulative catch-up adjustment related to updated ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Foghorn Therapeutics Inc. (FHTX) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2026. This widely-known ...
Hosted on MSN
Wall Street analysts think Foghorn Therapeutics (FHTX) could surge 67.01%: Read this before placing a bet
Shares of Foghorn Therapeutics Inc. (FHTX) have gained 33.5% over the past four weeks to close the last trading session at $6 ...
Foghorn Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported net income was USD 58.15 million ...
Foghorn Therapeutics, a biotech whose technology can affect one of the ways a cell regulates gene expression, has shown its approach has the potential to address a particular mutation tied to more ...
The partial clinical hold announced after the market close Thursday permits patients currently enrolled in the Phase 1 dose-escalation study to continue receiving the experimental Foghorn drug, FHD286 ...
SUNNYVALE, Calif.--(BUSINESS WIRE)--FogHorn, a leading developer of Edge AI software for industrial and commercial Internet of Things (IoT) solutions, today announced its ranking as the Overall Leader ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results